Dr. Sudipto Das completed a Bachelor’s in Technology (B.Tech) - Biotechnology (honours) from Rai Foundation Colleges, Yashwantrao Chavan Maharashtra Open University, Mumbai, India in 2007, followed by a M.Res – Biomedical Sciences, University of Glasgow, U.K in 2008. Subsequently, Dr. Das obtained his PhD in cancer genetics under the supervision of Prof. Raymond Stallings in 2012. He has also spent time as a visiting research fellow in VIB, K.U., Leuven, VuMC, Amsterdam and Hoshi University, Tokyo Japan. His doctoral work gave him the opportunity to develop a core expertise in the area of epigenetics focused on DNA methylation alterations and non-coding RNAs, which he further enhanced during his Post-doctoral career. This has allowed Dr. Das to obtain prestigious fellowship from organizations such as the Irish Cancer Society, obtain several awards, develop various national and international collaborations and publish highly cited peer review articles in high-impact scientific journals (including Cancer Research, Oncogene, JCI, Nat Comms, JCO, Cancer Discovery). Dr. Das’s key research focus involves application of genomics and epigenomics approaches across a several diseases especially cancer and inflammatory bowel diseases as well as heart failure, with the aim to identifying potential predictive/prognostic biomarkers and/or therapeutic targets that can ultimately aid in enhancing better patient care. His expertise has in turn allowed him to develop various international and national collaboration leading to successful funding applications from British Heart Foundation and Heart Research U.K and Japan Society for Promotion of Science. To date, Dr. Das has accrued >3.5 million euro in funding from national and international funding agencies inlcuding Research Ireland, Health Research Board, Enterprise Ireland and European Crohn's and Colitis foundation, allowing him to establish the "Epigenetics in Gastrointestinal research group". The research group primarily focusses on identifying the role of epigenetic modification as novel biomarkers and therapeutic targets in GI diseases. Dr. Das has led development and expansion of an award winning M.Sc - Technologies & Analytics in Precision medicine established in 2021 funded by the Higher Education Authority - Human Captial Iniative grant. The graduates of this programme continue to gain emplyment in leading companies such as EY, Pfizer, Grifols as well as secure prestigious PhD positions. As Vice Dean for AI and digital, connected health at RCSI, Dr. Das aims to lead the University to effectively embed AI and digital health-associated applications and concepts in research, education as well as operations/service efficiency.
